70 years, 21,500 hearts a year, 1,500+ transplants
Fuwai Hospital is, in the most literal sense, a hospital with one job. Founded in 1956 as the People's Liberation Army Chest Hospital, it was renamed Fuwai in 1958 and rebuilt as a civilian cardiovascular specialty centre. It has treated hearts almost exclusively for the past seven decades. In 2009, the State Council designated it the home of the National Center for Cardiovascular Diseases, an administrative arrangement that effectively made one hospital the policy coordinator, training hub, and clinical reference for the entire country's heart-disease system.
In 2024 alone, Fuwai performed 21,516 cardiac surgical operations — the second-highest single-centre volume in China and the highest in Asia — and supported 15,420 cardiopulmonary bypass procedures from its 28 dedicated operating rooms. Since 2004, the hospital's transplant team has performed 1,544 heart transplants, by far the largest cumulative programme on the continent, with an in-hospital survival rate of 96.0% and a 10-year overall survival of 76.0% — both meaningfully above international averages. In the 2024 Fudan Hospital Specialty Reputation Rankings, Fuwai held the No.1 spot in both cardiovascular medicine and cardiac surgery for the fifteenth consecutive year, the only hospital in China to lead both disciplines at once.
What the place actually looks like
Fuwai's clinical structure is unusual: a single hospital with so many sub-specialty cardiac units that the total bed count is the largest of any cardiovascular centre in the world. The adult cardiac surgery service is split across wards, each handling around 1,200 to 1,400 open-heart operations a year. Ward Two — historically led by surgeons including Academician Zhu Xiaodong, the current hospital president Academician Hu Shengshou, and Professor Song Yunhu — performs around 800 coronary artery bypass graft (CABG) operations a year, of which roughly 90% are high-risk cases; its 2024 mortality for CABG was about 0.5%, against the 2.3% reported for the same procedure in the United States in the 2008 Society of Thoracic Surgeons registry. The hospital's heart-failure and transplantation service runs one of the largest mechanical circulatory support programmes in the world, including left ventricular assist devices and the domestically developed magnetic-levitation "artificial heart" that won a 2023 national science award.
Fuwai's training role is just as striking. More than 60% of the country's certified cardiopulmonary bypass perfusionists have been trained at Fuwai. The hospital hosts the National Center for Cardiovascular Diseases, the State Key Laboratory of Cardiovascular Disease, and the National Clinical Research Center for Cardiovascular Diseases — three separate national-level platforms under one roof. It also publishes the annual Report on Cardiovascular Diseases in China, the most-cited dataset on heart disease in the country, and operates a nationwide telemedicine network that links more than 1,500 partner hospitals.
Why it became No.1
Three factors explain Fuwai's fifteen-year grip on the top ranking. First, scale that no domestic competitor can match: the 2024 white paper on Chinese cardiovascular surgery and cardiopulmonary bypass recorded 21,516 operations at Fuwai, against 23,388 at Beijing Anzhen (the only larger centre) — but Fuwai's caseload is more evenly spread across every cardiac sub-specialty, and its bypass volume is the largest in the country. Second, a generational handover that the country's political and academic system is uniquely positioned to organise: the transition from Academician Zhu Xiaodong to Academician Hu Shengshou kept the centre's strategy and operating culture intact for almost four decades. Third, the dual "centre plus hospital" structure created in 2009, which means the hospital does not merely treat the most difficult cases — it writes the clinical guidelines, trains the specialists, and designs the screening protocols that the rest of the country uses.
The results, measured in outcomes rather than reputation, are clear. Fuwai's open-heart surgical mortality has stayed below 1% for thirteen consecutive years. Its CABG mortality of around 0.5% in 2024 is roughly a quarter of the figure reported in most Western centres. The 10-year survival of 76% for its heart transplant patients exceeds the international average reported by the International Society for Heart and Lung Transplantation.
What this means for international patients
For a foreign patient considering cardiac treatment in China, Fuwai is the place the rest of the Chinese system refers to when it runs out of options. The hospital runs an international patient office, an English-language website, and a multilingual consultation service; its affiliated Fuwai Shenzhen Hospital and Fuwai Central China Cardiovascular Hospital (in Zhengzhou) extend the same model into southern and central China. The hospital accepts overseas patients for coronary artery bypass grafting, valve repair and replacement, complex aortic surgery, congenital heart disease in adults, heart failure management including mechanical circulatory support, and heart transplantation evaluation. Patients from neighbouring countries — Mongolia, Southeast Asia, the Middle East — already travel to Fuwai for these procedures; English-language case coordination and remote pre-operative assessment are available.
The address is 167 Beilishi Road, Xicheng District, Beijing. The hospital's English-language site is at fuwai.com. This profile is editorial information based on the sources linked below, not treatment advice; individual outcomes depend on the condition, the team, and the patient.